S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
These 2 Healthcare Stocks Have Doubled in 2023
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
Bed Bath & Beyond Is Circling the Drain
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Know Your Profit Potential BEFORE You Trade! (Ad)pixel
AMD Results Are No Reason To Buy Semiconductors... Yet
Institutions are Buying up Procter & Gamble Shares, Should you?
NASDAQ:RGNX

REGENXBIO - RGNX Price Target & Analyst Ratings

$23.47
+0.26 (+1.12%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$22.87
$23.65
50-Day Range
$21.76
$24.55
52-Week Range
$18.69
$35.73
Volume
492,268 shs
Average Volume
327,047 shs
Market Capitalization
$1.02 billion
P/E Ratio
15.14
Dividend Yield
N/A
Price Target
$41.43

REGENXBIO Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Moderate Buy
Based on 6 Analyst Ratings

Consensus Analyst Price Target

$41.43
76.52% Upside
High Prediction$61.00
Average Prediction$41.43
Low Prediction$14.00
TypeCurrent
2/2/22 to 2/2/23
1 Month Ago
1/3/22 to 1/3/23
3 Months Ago
11/4/21 to 11/4/22
1 Year Ago
2/2/21 to 2/2/22
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
4 Buy rating(s)
Hold
2 Hold rating(s)
2 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$41.43$41.43$41.71$52.86
Predicted Upside76.52% Upside82.28% Upside74.46% Upside43.52% Upside
Get REGENXBIO Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.


RGNX Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

RGNX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

REGENXBIO Stock vs. The Competition

TypeREGENXBIOMedical CompaniesS&P 500
Consensus Rating Score
2.67
2.65
2.46
Consensus RatingModerate BuyBuyHold
Predicted Upside76.52% Upside1,301.26% Upside8.14% Upside
News Sentiment RatingPositive News
Positive News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/23/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetMarket Perform$15.00 ➝ $14.00-38.24%
11/21/2022Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$52.00 ➝ $50.00+131.48%
11/4/2022Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$70.00 ➝ $61.00+189.79%
10/4/2022Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Andreas Argyrides
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetNeutral$32.00 ➝ $28.00+15.85%
10/4/2022Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$47.00 ➝ $29.00+19.98%
6/23/2022Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$61.00+155.34%
6/23/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy$51.00 ➝ $47.00+96.73%
10/25/2021Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$15.00 ➝ $17.00-53.49%
9/14/2021Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$79.00 ➝ $82.00+88.94%
1/6/2021Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeOutperform ➝ Strong-Buy$60.00+33.60%
6/25/2020Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$60.00+61.73%
(Data available from 2/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












RGNX Price Target - Frequently Asked Questions

What is REGENXBIO's consensus rating and price target?

According to the issued ratings of 6 analysts in the last year, the consensus rating for REGENXBIO stock is Moderate Buy based on the current 2 hold ratings and 4 buy ratings for RGNX. The average twelve-month price prediction for REGENXBIO is $41.43 with a high price target of $61.00 and a low price target of $14.00. Learn more on RGNX's analyst rating history.

Do Wall Street analysts like REGENXBIO more than its competitors?

Analysts like REGENXBIO more than other Medical companies. The consensus rating for REGENXBIO is Moderate Buy while the average consensus rating for medical companies is Buy. Learn more on how RGNX compares to other companies.

Does REGENXBIO's stock price have much upside?

According to analysts, REGENXBIO's stock has a predicted upside of 80.30% based on their 12-month price targets.

What analysts cover REGENXBIO?

REGENXBIO has been rated by Chardan Capital, Morgan Stanley, and SVB Leerink in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:RGNX) was last updated on 2/2/2023 by MarketBeat.com Staff